Direct hyperbilirubinemia in newborns with gastroschisis
Patients with gastroschisis and prolonged total (or partial) parenteral nutrition (PN) commonly develop direct hyperbilirubinemia (DH).
To quantify the prevalence and severity of DH in newborns with gastroschisis and characterize the diagnostic work-up for DH in this patient population.
Retrospective chart review of patients born with gastroschisis between 2005 and 2015 for the first 6 months of life.
29 patients were identified with gastroschisis. Mean gestational age and birthweight were 36.4 (± 1.8) weeks and 2.5 (± 0.6) kg. 41% were treated with primary reduction versus staged closure. Peak total and direct bilirubin (DB) levels were 10.17 ± 6.21 mg/dL and 5.58 ± 3.94 mg/dL, respectively. 23 patients (79.3%) were diagnosed with DH and 78.2% underwent additional work-up for hyperbilirubinemia consisting of imaging and laboratory studies, none of which revealed a cause for DH other than the presumed PN-associated cholestasis. In all patients, DB began to decline within 1–10 days of initiation of enteral feeds.
DH is common in patients with gastroschisis and is unlikely to be associated with pathology aside from PN. Additional work-up may lead to unnecessary resource utilization.
Levels of evidence
Case series with no comparison group, Level IV.
KeywordsDirect hyperbilirubinemia Gastroschisis Resource utilization Cholestasis Outcomes
Parenteral nutrition associated liver disease
North American Society for pediatric gastroenterology, hepatology, and nutrition
Day of life
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The need for informed consent was waived by the Institutional Review Board as the study was felt to pose less than minimal risk by its nature as a retrospective review.
- 8.Diamanti A, Basso MS, Castro M, Calce A, Pietrobattista A, Gambarara M (2007) Prevalence of life-threatening complications in pediatric patients affected by intestinal failure. Transplant Proc 39(5):1632–1633. https://doi.org/10.1016/j.transproceed.2007.02.083 CrossRefPubMedGoogle Scholar
- 9.Diamond IR, de Silva N, Pencharz PB, Kim JH, Wales PW (2007) Neonatal short bowel syndrome outcomes after the establishment of the first Canadian multidisciplinary intestinal rehabilitation program: preliminary experience. J Pediatr Surg 42(5):806–811. https://doi.org/10.1016/j.jpedsurg.2006.12.033 CrossRefPubMedGoogle Scholar
- 11.Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, Karpen SJ (2017) Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for pediatric gastroenterology, hepatology, and nutrition and the european society for pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr 64(1):154–168. https://doi.org/10.1097/MPG.0000000000001334 CrossRefPubMedGoogle Scholar
- 19.Jensen AR, Goldin AB, Koopmeiners JS, Stevens J, Waldhausen JH, Kim SS (2009) The association of cyclic parenteral nutrition and decreased incidence of cholestatic liver disease in patients with gastroschisis. J Pediatr Surg 44(1):183–189. https://doi.org/10.1016/j.jpedsurg.2008.10.033 CrossRefPubMedGoogle Scholar
- 20.Lauriti G, Zani A, Aufieri R, Cananzi M, Chiesa PL, Eaton S, Pierro A (2014) Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. JPEN J Parenter Enteral Nutr 38(1):70–85. https://doi.org/10.1177/0148607113496280 CrossRefPubMedGoogle Scholar
- 24.Messing B, Pontal PJ, Bernier JJ (1983) Metabolic study during cyclic total parenteral nutrition in adult patients with and without corticosteroid-induced hypercatabolism: comparison with standard total parenteral nutrition. JPEN 7(1):21–25. https://doi.org/10.1177/014860718300700121 CrossRefGoogle Scholar
- 27.Moyer V, Freese DK, Whitington PF, Olson AD, Brewer F, Colletti RB (2004) North American Society for Pediatric Gastroenterology, H. p. a. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 39(2):115–128 N.CrossRefGoogle Scholar
- 30.Raimondi F, Indrio F, Crivaro V, Araimo G, Capasso L, Paludetto R (2008) Neonatal hyperbilirubinemia increases intestinal protein permeability and the prevalence of cow’s milk protein intolerance. Acta Paediatr 97(6):751–753. https://doi.org/10.1111/j.1651-2227.2008.00746.x CrossRefPubMedGoogle Scholar
- 31.Rangel S, Calkins C, Cowles R, Barnhart D, Huang E, Abdullah F, Teitelbaum D (2012) Parenteral nutrition–associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. 47(1), 225–240. https://doi.org/10.1016/j.jpedsurg.2011.10.007 CrossRefGoogle Scholar